Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, following Single- and Multiple-Ascending Doses in Healthy Adults

Introduction: Toxic gain-of-function Apolipoprotein L1 (APOL1) variants contribute to the development of proteinuric nephropathies collectively referred to as APOL1-mediated kidney disease (AMKD). Despite standard-of-care treatments, patients with AMKD experience accelerated progression to end-stage...

Full description

Bibliographic Details
Main Authors: Ogo Egbuna, Vincent Audard, George Manos, Simon Tian, Fanuel Hagos, Glenn M. Chertow
Format: Article
Language:English
Published: Karger Publishers 2024-03-01
Series:Glomerular Diseases
Subjects:
Online Access:https://beta.karger.com/Article/FullText/538255